Molecular determinants of resistance to CDK4/6 inhibition in ER plus breast cancer

被引：0
|
作者：
Luo, F. [1 ,2 ]
Cowley, G. [3 ]
Garraway, L. [1 ,2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Broad Inst, Med Oncol, Boston, MA USA
[3] Janssen Pharmaceut Co, Johnson & Johnson, Funct Genom, Discovery Sci, Perkasie, PA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32819-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
224
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [41] Investigating CDK4/6 inhibition in triple negative breast cancer
    Guo, Qiuchen
    Goreczny, Gregory J.
    Spasic, Milos
    Maynard, Adam
    McAllister, Sandra S.
    CANCER RESEARCH, 2021, 81 (04)
  • [42] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
    Yang, C.
    Li, Z.
    Bhatt, T.
    Dickler, M.
    Giri, D.
    Scaltriti, M.
    Baselga, J.
    Rosen, N.
    Chandarlapaty, S.
    ONCOGENE, 2017, 36 (16) : 2255 - 2264
  • [43] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
    C Yang
    Z Li
    T Bhatt
    M Dickler
    D Giri
    M Scaltriti
    J Baselga
    N Rosen
    S Chandarlapaty
    Oncogene, 2017, 36 : 2255 - 2264
  • [44] Inhibition of CDK4/6 induces senescence and autophagy in ER positive breast cancers
    Vijayaraghavan, Smruthi
    Keyomarsi, Khandan
    CANCER RESEARCH, 2015, 75
  • [45] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
    Pandey, Kamal
    CANCER RESEARCH, 2020, 80 (16)
  • [46] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
  • [47] Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
    Li, Zhen
    Zou, Wei
    Zhang, Ji
    Zhang, Yunjiao
    Xu, Qi
    Li, Siyuan
    Chen, Ceshi
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [48] Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
    Pandey, Kamal
    Park, Nahee
    Park, Kyung-Soon
    Hur, Jin
    Cho, Yong Bin
    Kang, Minsil
    An, Hee-Jung
    Kim, Sewha
    Hwang, Sohyun
    Moon, Yong Wha
    CANCERS, 2020, 12 (12) : 1 - 17
  • [49] Molecular profiling of ER plus metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.
    Razavi, Pedram
    dos Anjos, Carlos Henrique
    Brown, David N.
    Qing, Li
    Ping, Christina
    Herbert, Joshua
    Colon, Jodecy
    Liu, Dazhi
    Mao, Maiya
    Norton, Larry
    Scaltriti, Maurizio
    Solit, David B.
    Robson, Mark E.
    Reis-Filho, Jorge S.
    Jhaveri, Komal L.
    Chandarlapaty, Sarat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Breast cancer: CDK4/6 inhibitor plus fulvestrant prolongs survival
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02)
12345